{"id":138,"date":"2021-09-27T08:48:36","date_gmt":"2021-09-27T08:48:36","guid":{"rendered":"http:\/\/cetaitdemain.org\/?p=138"},"modified":"2021-09-27T08:48:36","modified_gmt":"2021-09-27T08:48:36","slug":"%ef%bb%bfin-the-flank-of-a-wt-and-b-il-9ko-mice","status":"publish","type":"post","link":"https:\/\/cetaitdemain.org\/?p=138","title":{"rendered":"\ufeffin the flank of (A) WT and (B) IL-9ko mice"},"content":{"rendered":"

\ufeffin the flank of (A) WT and (B) IL-9ko mice. that prevents the formation of immunologic memory to a growing tumor, highlighting the potential for IL-9 neutralization as a unique tool for cancer immunotherapy. Introduction IL-9 is a paradoxical cytokine, as it mediates both pro-inflammatory events and induction of tolerance. It is secreted by a host of pro-inflammatory immune cells including Th9 cells (1), Th17 cells (2), CD8+ Tc9 cells (3), eosinophils, mast cells, and innate lymphoid cells (1, 4C7). It is also associated with tolerogenic cells such as T regulatory cells (Tregs). In this population IL-9 enhances Treg suppressive potency in an autocrine fashion (8), while promoting T cell tolerance via a paracrine impact upon mast cells (9C11). This wide range of action is followed by an equally wide range of pathologies involving IL-9 secretion. Most commonly, IL-9 is linked to Th2 responses such as parasite expulsion and allergic airway inflammation, but it is also involved in autoimmunity and graft-versus-host disease (reviewed in (6)). Interestingly, IL-9 can be secreted by cells that promote opposite ends of the immune-spectrum. For example: pro-inflammatory Th17 cells can produce IL-9 and exacerbate experimental autoimmune encephalitis (EAE) (12), whereas IL-9 secreted by Tregs Thbs2<\/a> renders them more suppressive and protects against EAE (8). These discrepancies may be explained by the timing of IL-9 secretion in a given pathologic circumstance, and by the range of cells that express the IL-9 receptor (IL9R). These include Tregs, CD4+ T cells, B cells and dendritic cells (expression data from the Immunological Genome Project), as well as CD3+ T cells and CD11b+ Gr1+ cells from tumor-bearing mice. IL-9 also has seemingly contradictory roles in tumor biology. In many tumors the presence of IL-9 contributes to the establishment of a tolerogenic \/ immunosuppressive environment, or acts directly to drive tumor growth. For example, IL-9 promotes the proliferation or survival of human lymphoid tumors such as Hodgkins lymphoma, acute lymphoblastic leukemia, myeloid leukemia, diffuse large B cell lymphoma and NK T cell lymphoma (13C18). It also promotes the proliferation, migration and adhesion of human lung Betrixaban cancer cells (19). However, IL-9 has the opposite effect on melanoma Betrixaban biology: it slows sub-cutaneous growth of B16F10 as well as reducing B16 seeding in the lungs (20, 21), both groups showed that anti-IL9 opposes this effect. Adoptively transferred IL-9 secreting CD4+ T cells (25% IL-9 positivity) reduce melanoma growth, in a manner that is very similar to the transfer of Th2 polarized T cells (20). In addition polarized OT-1 CD8+ T cells (Tc9), adoptively transferred to B16-OVA tumor bearing mice, led to tumor clearance (22). However, the authors point out that two weeks after transfer, Tc9 cells loose IL-9 expression and instead, secrete IFN, suggesting a repolarization to a Tc1 phenotype, which could explain the efficient tumor clearance. In the B16 tumor model, IL-9 acts on mast cells, and is not T or B cell dependent (20), and also has a direct effect on the lung epithelium, which then recruits dendritic cells (21). Study of the role of IL-9 in Betrixaban mammary carcinomas is limited to a longitudinal study of soluble factors present in sera of breast cancer patients. Investigators found an increase in serum Betrixaban<\/a> levels of IL-9 over time in patients that later developed metastatic lesions, suggesting a relationship between IL-9 and tumor progression, or tumor load (23). In summary, the majority of.<\/p>\n","protected":false},"excerpt":{"rendered":"

\ufeffin the flank of (A) WT and (B) IL-9ko mice. that prevents the formation of immunologic memory to a growing tumor, highlighting the potential for IL-9 neutralization as a unique tool for cancer immunotherapy. Introduction IL-9 is a paradoxical cytokine, as it mediates both pro-inflammatory events and induction of tolerance. It is secreted by a …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"class_list":["post-138","post","type-post","status-publish","format-standard","hentry","category-pde","entry entry-center"],"_links":{"self":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=138"}],"version-history":[{"count":1,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/138\/revisions"}],"predecessor-version":[{"id":139,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=\/wp\/v2\/posts\/138\/revisions\/139"}],"wp:attachment":[{"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cetaitdemain.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}